News
-
-
-
PRESS RELEASE
Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill
Protagonist Therapeutics reports 84% of adolescents with moderate-to-severe plaque psoriasis achieved clear skin at Week 16 with icotrokinra in the ICONIC-LEAD Phase 3 study, showing potential as a first-line therapy -
-
-
PRESS RELEASE
Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025
Protagonist Therapeutics named one of Fast Company's Most Innovative Companies 2025 for pioneering peptide-based therapeutics. Recognized for groundbreaking work in drug development -
-
-
PRESS RELEASE
Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis
Protagonist Therapeutics, Inc. announces positive topline results from ANTHEM-UC Phase 2b study of icotrokinra in ulcerative colitis, meeting primary endpoint. Results indicate high clinical response and remission rates -
